TGFB1 and glioblastoma: As recently reviewed by Vaz-Salgato et al. (2023) [18], various second-line chemotherapeutics have been tested for the treatment of GBM, including anti-vascular endothelial growth factor (VEGF) [19,20,21], anti-transforming growth factor β (TGFβ)-receptor-I [22], anti-receptor tyrosine kinase [23], anti-protein kinase C [24], anti-EGFR [25], and anti-tyrosine kinase [26].